Self-Emulsifying Formulations to Increase the Oral Bioavailability of 4,6,4′-Trimethylangelicin as a Possible Treatment for Cystic Fibrosis

Self-Emulsifying Formulations to Increase the Oral Bioavailability of 4,6,4′-Trimethylangelicin as a Possible Treatment for Cystic Fibrosis

4,6,4′-trimethylangelicin (TMA) is a promising pharmacological option for the treatment of cystic fibrosis (CF) due to its triple-acting behavior toward the function of the CF transmembrane conductance regulator. It is a poorly water-soluble drug, and thus it is a candidate for developing a self-emu...

Full description

Bibliographic Details
Main Authors: Erica Franceschinis, Marco Roverso, Daniela Gabbia, Sara De Martin, Matteo Brusegan, Christian Vaccarin, Sara Bogialli, Adriana Chilin
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceutics
Subjects:
TMA
cystic fibrosis
SEDDS
oral bioavailability
Online Access:https://www.mdpi.com/1999-4923/14/9/1806

Similar Items

Similar Items